US20180221145A1 - Valve prosthesis - Google Patents

Valve prosthesis Download PDF

Info

Publication number
US20180221145A1
US20180221145A1 US15/945,514 US201815945514A US2018221145A1 US 20180221145 A1 US20180221145 A1 US 20180221145A1 US 201815945514 A US201815945514 A US 201815945514A US 2018221145 A1 US2018221145 A1 US 2018221145A1
Authority
US
United States
Prior art keywords
leaflet
frame
valve
angle
free portion
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US15/945,514
Inventor
Carol EBERHARDT
Tomas MCNATT
Pham LO
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Medtronic CV Luxembourg SARL
Original Assignee
Medtronic CV Luxembourg SARL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medtronic CV Luxembourg SARL filed Critical Medtronic CV Luxembourg SARL
Priority to US15/945,514 priority Critical patent/US20180221145A1/en
Assigned to Medtronic CV Luxembourg S.a.r.l. reassignment Medtronic CV Luxembourg S.a.r.l. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: LO, Pham, MCNATT, Tomas, EBERHARDT, Carol
Publication of US20180221145A1 publication Critical patent/US20180221145A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/02Prostheses implantable into the body
    • A61F2/24Heart valves ; Vascular valves, e.g. venous valves; Heart implants, e.g. passive devices for improving the function of the native valve or the heart muscle; Transmyocardial revascularisation [TMR] devices; Valves implantable in the body
    • A61F2/2412Heart valves ; Vascular valves, e.g. venous valves; Heart implants, e.g. passive devices for improving the function of the native valve or the heart muscle; Transmyocardial revascularisation [TMR] devices; Valves implantable in the body with soft flexible valve members, e.g. tissue valves shaped like natural valves
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/02Prostheses implantable into the body
    • A61F2/24Heart valves ; Vascular valves, e.g. venous valves; Heart implants, e.g. passive devices for improving the function of the native valve or the heart muscle; Transmyocardial revascularisation [TMR] devices; Valves implantable in the body
    • A61F2/2412Heart valves ; Vascular valves, e.g. venous valves; Heart implants, e.g. passive devices for improving the function of the native valve or the heart muscle; Transmyocardial revascularisation [TMR] devices; Valves implantable in the body with soft flexible valve members, e.g. tissue valves shaped like natural valves
    • A61F2/2418Scaffolds therefor, e.g. support stents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2220/00Fixations or connections for prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
    • A61F2220/0025Connections or couplings between prosthetic parts, e.g. between modular parts; Connecting elements
    • A61F2220/0075Connections or couplings between prosthetic parts, e.g. between modular parts; Connecting elements sutured, ligatured or stitched, retained or tied with a rope, string, thread, wire or cable
    • FMECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
    • F04POSITIVE - DISPLACEMENT MACHINES FOR LIQUIDS; PUMPS FOR LIQUIDS OR ELASTIC FLUIDS
    • F04CROTARY-PISTON, OR OSCILLATING-PISTON, POSITIVE-DISPLACEMENT MACHINES FOR LIQUIDS; ROTARY-PISTON, OR OSCILLATING-PISTON, POSITIVE-DISPLACEMENT PUMPS
    • F04C2270/00Control; Monitoring or safety arrangements
    • F04C2270/04Force
    • F04C2270/042Force radial
    • F04C2270/0421Controlled or regulated

Definitions

  • the present invention is related to artificial heart valves. More specifically, the present invention is directed to an artificial valve prosthesis.
  • Regurgitation is the more common of the two defects.
  • either defect is treated by a surgical repair.
  • the cardiac valve must be replaced.
  • Standard approaches to valve replacement require cutting open the patient's chest and heart to access the native valve. Such procedures are traumatic to the patient, require a long recovery time, and can result in life threatening complications. Therefore, many patients requiring cardiac valve replacement are deemed to pose too high a risk for open heart surgery due to age, health, or a variety of other factors.
  • These patient risks associated with heart valve replacement are lessened by the emerging techniques for minimally invasive valve repair, but still many of those techniques require arresting the heart and passing the blood through a heart-lung machine.
  • a valve prosthesis is compacted for delivery in a catheter and then advanced, for example, through an opening in the femoral artery and through the descending aorta to the heart, where the prosthesis is then deployed in the aortic valve annulus.
  • valve prosthesis that is capable of conforming to a patient's anatomy while providing a uniform degree of rigidity and protection for critical valve components. Protection for critical valve components is essential to maintain reliability for the valve prosthesis.
  • valve prostheses that generally include a self-expanding frame, where the valve prostheses are sutured to the self-expanding frame.
  • Such configurations achieve numerous goals. For example, such configurations can: prevent the native leaflets from obstructing flow through the left ventricular outflow tract (LVOT); prevent the native leaflets from interacting with the prosthetic leaflets; recruit the native leaflets in minimizing perivalvular leaks; maintain proper alignment of the valve prosthesis; avoid systolic anterior mobility; and maintain valve stability by preventing migration of the valve into the atrium or ventricle.
  • the design of the prosthesis also mimics the native valve and supports a non-round in vivo configuration, which better reproduces native valve function.
  • a valve prosthesis which is generally designed to include a valve body and a self expanding frame.
  • the valve body includes a first leaflet, a second leaflet, and a third leaflet. Adjoining leaflets are sewn together to form a first commissure point, a second commissure point, a third commissure point, and a fourth commissure point. The four commissure points are sewn to the frame.
  • the valve prosthesis is designed to include a valve body including a first leaflet, a second leaflet, a third leaflet, and a fourth leaflet, and a self expanding frame.
  • the first leaflet is attached to the second leaflet at a first point to form a first commissure point.
  • the second leaflet is attached to the third leaflet at a second point to form a second commissure point.
  • the third leaflet is attached to the fourth leaflet at a third point to form a third commissure point.
  • the commissure points are sewn to the frame.
  • the valve prosthesis includes a valve body and a self-expanding frame.
  • the valve body includes a first leaflet, a second leaflet, and a third leaflet. Adjoining leaflets are sewn together to form a first commissure point, a second commissure point, a third commissure point, and a fourth commissure point. The four commissure points are sewn to the frame.
  • FIG. 1 is a perspective view of a valve prosthesis, in accordance with an aspect of the disclosure.
  • FIG. 2 is a side view of a valve prosthesis.
  • FIG. 3 is a top view of a valve prosthesis.
  • FIG. 4 is a top view of a valve prosthesis according to an alternate aspect of this disclosure.
  • FIG. 5 is a top view of a valve prosthesis according to an alternate aspect of this disclosure.
  • FIG. 6 is a top view of a valve prosthesis according to an alternate aspect of this disclosure.
  • FIG. 7 is a top view of a valve prosthesis according to an alternate aspect of this disclosure.
  • FIG. 8 is a top view of a valve prosthesis according to an alternate aspect of this disclosure.
  • valve prosthesis refers to the accompanying figures that illustrate exemplary embodiments. Other embodiments are possible. Modifications can be made to the embodiments described herein without departing from the spirit and scope of the present invention. Therefore, the following detailed description is not meant to be limiting.
  • the present invention is directed to a heart valve prosthesis having a self-expanding frame that supports a valve body.
  • the valve prosthesis can be delivered percutaneously to the heart to replace the function of a native valve.
  • the valve prosthesis can replace a bicuspid or a tricuspid valve such as the aortic, mitral, pulmonary, or tricuspid heart valve.
  • the valve body comprises three leaflets that are fastened together at enlarged lateral end regions to form commissural joints, with the unattached edges forming the coaptation edges of the valve.
  • the leaflets can be fastened to a skirt, which in turn can be attached to the frame.
  • the upper ends of the commissure points define an outflow or proximal portion of the valve prosthesis.
  • the opposite end of the valve at the skirt defines an inflow or distal portion of the valve prosthesis.
  • the enlarged lateral end regions of the leaflets permit the material to be folded over to enhance durability of the valve and reduce stress concentration points that could lead to fatigue or tearing of the leaflets.
  • the commissural joints are attached above the plane of the coaptation edges of the valve body to minimize the contacted delivery profile of the valve prosthesis.
  • valve prosthesis 1 includes a circular frame 11 .
  • Frame 11 can be any non-biological structure including wireforms, stents, and the like.
  • frame 11 can be elliptical, D-shaped, or any other shape known to a person of ordinary skill in the art.
  • frame 11 can be tapered, cylindrical, conical, or any other shape known to a person of ordinary skill.
  • Frame 11 can be a self-expanding structure formed by laser cutting or etching a metal alloy tube comprising, for example a shape memory material such as nickel titanium (nitinol).
  • frame 11 can be a balloon expanding structure.
  • Frame 11 can include a pattern of radial cells that make up the structure of frame 11 .
  • the cell sizes can be modified during the formation of frame 11 , for example through an expansion step.
  • the number of cells in a radial or axial direction can be modified to allow for a larger or fewer number of cells.
  • Frame 11 can also include a cusp 91 .
  • Cusp 91 can be a radiopaque imaging reference to assist in positioning the valve prosthesis 1 in a native valve annulus.
  • Cusp 91 can also assist in anchoring frame 11 in the native valve annulus.
  • Valve prosthesis 1 also includes a valve 21 that includes individual leaflets that are assembled to the skirt.
  • the leaflets and skirt are formed from a natural or man-made material.
  • Preferred materials for valve 21 include mammalian tissue, such as porcine, equine, or bovine pericardium, or a synthetic or polymeric material.
  • valve 21 includes three leaflets 31 a - c . Adjoining pairs of leaflets are attached to one another to form commissure points 41 a - d .
  • Leaflet 31 b is attached to leaflet 31 a by commissure points 41 a and 41 d .
  • Leaflet 31 b is attached to leaflet 31 c by commissure points 41 b and 41 c .
  • valve prosthesis 1 is biased to a closed position.
  • valve prosthesis 1 can be biased to an open position.
  • Free edges of leaflets 31 b and 31 a come together to form coaptation edge 51 a , thereby creating a competent seal.
  • Free edges of leaflets 31 b and 31 c come together to form coaptation edge 51 b , thereby creating a competent seal.
  • the length of coaptation edges 51 a and 51 b can be from approximately 24 mm to approximately 48 mm. In a preferred embodiment, the length of coaptation edges 51 a and 51 b is approximately 25 mm.
  • the contact area between the leaflets at coaptation edges 51 a and 51 b is minimized to allow for quicker opening and closing of valve leaflets 31 a - c .
  • the contact area of the leaflets at coaptation edges 51 a and 51 b is affected by the positioning of valve prosthesis 1 in the native anatomy.
  • valve prosthesis 1 takes approximately 0.06 seconds to open from a closed configuration.
  • Valve prosthesis 1 takes approximately 0.04 seconds to close from an open configuration.
  • Valve prosthesis 1 is also able to operate at approximately 167 ml/second of fluid.
  • Valve prosthesis 1 can include center member 81 .
  • center member 81 attaches to frame 11 between commissure points 41 a and 41 b and between commissure points 41 c and 41 d .
  • Center member 81 can be semi-rigid or rigid and can be a suture, nitinol wire, or a synthetic or polymeric material that will not generate a thrombotic response in a patient, or any other material known to a person of ordinary skill in the art.
  • center member 81 is attached to frame 11 on the outflow side of leaflet 31 b .
  • center member 81 can be attached to frame 11 on the inflow side of leaflet 31 b .
  • Center member 81 restricts the movement of leaflet 31 b and prevents leaflet 31 b from collecting blood and parachuting in the outflow direction in the presence of blood flow. As a result, during blood flow, the free edges of leaflet 31 b fold along center member 81 and minimize the area of leaflet 31 b extending across the orifice area of valve prosthesis 1 .
  • each commissure point is attached to frame 11 by sewing the commissure point to a cell of frame 11 such that each commissure point occupies an entire cell of frame 11 .
  • each commissure point can be attached to frame 11 by sewing the commissure point to a portion of a cell of frame 11 .
  • at least one cell of frame 11 is positioned between commissure points 41 a and 41 b and commissure points 41 c and 41 d .
  • at least two cells can be positioned between commissure points 41 b and 41 c and commissure points 41 a and 41 d .
  • commissure points 41 a - d are disposed longitudinally offset from coaptation edges 51 a - b of the valve body, thereby permitting a smaller delivery profile.
  • valve prosthesis 1 may require a delivery system that features an asymmetric member so that the delivery system doesn't interfere with leaflet 31 b .
  • a delivery system for valve prosthesis 1 can grasp the outer edge of frame 11 to deliver valve prosthesis 1 into a native valve annulus.
  • the axial distance from the distal most portion of the base of the valve leaflets to the proximal most portion of the valve leaflets is the leaflet height, h 2 .
  • the base of the valve leaflets is where the leaflet edges attach to the skirt and the valve frame.
  • h 2 is from approximately 8 mm to approximately 15 mm.
  • the axial distance between the distal and proximal portions of the commissure points is the commissure height, h 1 . In a preferred embodiment, h 1 is approximately 9 mm.
  • FIG. 3 shows valve 21 in the closed state.
  • Commissure points 41 a - d attach to frame 11 and are positioned to form angles 61 a - d between the respective commissure points with the center of frame 11 as the vertex of the angles.
  • Angles 61 a and 61 c can be larger than angles 61 b and 61 d .
  • angles 61 a and 61 c are approximately 170 degrees.
  • one or more of angles 61 a - d can be modified to optimize the function of valve prosthesis 1 by positioning one or more commissure points 41 a - d at an alternate portion or cell of frame 11 or by modifying the shape of one or more of leaflets 31 a - c .
  • angles 61 a and 61 c can be between approximately 160 degrees and 180 degrees. Angles 61 a and 61 c can also be between 90 degrees and 180 degrees. Modifying one or more of angles 61 a - d can modify the length of coaptation edges 51 a and/or 51 b . A longer coaptation edge length correlates to less stress on commissure points 41 a - d.
  • leaflets 31 a and 31 c are approximately the same size.
  • leaflets 31 a and 31 c can be different sizes. Modifying the sizes of leaflets 31 a and 31 c can also affect angles 61 a - d . For example, if leaflets 31 a and 31 c are different sizes, angle 61 c can be larger than angle 61 a , or vice versa.
  • the configuration involving four commissure points can increase the coaptation length of the valve leaflets. As a result, the four commissure points experience less deflection than a valve having three commissure points. This allows the leaflets to maintain a rapid opening and closing time.
  • the four commissure design also enables the valve prosthesis to maintain reliability with a low commissure height.
  • the low commissure height allows valve prosthesis 1 to replace the native mitral valve.
  • a low commissure height correlates to a valve prosthesis that is shorter in the axial direction that is easier to position and align in a native valve annulus.
  • the four commissure points also enable the valve to maintain hemodynamic performance in a severely elliptical configuration by mitigating impact in the coaptive region.
  • This configuration also provides a more uniform distribution of stresses along coaptation edges 51 a - b of leaflets 31 a - c allowing valve prosthesis 1 to exhibit greater reliability and a longer operating life than current catheter delivered valve prostheses.
  • frame 13 is an hourglass shape where the outflow portion flares out such that the diameter of the outflow portion of the frame is larger than the diameter of the inflow portion of the frame.
  • commissure points 43 a - d are angled outward from the center of frame 13 . In this configuration, the most proximal portions of commissure points 43 a - d are further from the center of frame 13 than the distal portions of commissure points 43 a - d .
  • the commissure points can be angled inward towards the center of the frame.
  • the commissure points can also be oriented vertically on the frame, as shown in FIG. 3 .
  • FIGS. 5-6 are top views of alternative aspects of the invention showing alternate frame shapes.
  • the frame is an elliptical shape.
  • leaflets 35 a and 35 c have approximately the same size and area and angles 65 a and 65 c are approximately equal. In a preferred embodiment, angles 65 a and 65 c are approximately 170 degrees.
  • coaptation edges 55 a and 55 b are approximately equal in length. Similar to valve prosthesis 1 discussed in FIGS. 1-3 , the size and area of leaflets 35 a - c can be modified so that leaflets 35 a and 35 c do not have approximately the same size.
  • the placement of commissure points 45 a - d on frame 15 can also be modified to alter angles 65 a - d in order to optimize the function of valve prosthesis 5 .
  • leaflet 37 c can have a larger area than leaflet 37 a and corresponding angle 67 c can be greater than angle 67 a .
  • coaptation edge 57 b can have a greater length than coaptation edge 57 a .
  • leaflet 37 a can be larger than leaflets 37 c and corresponding angle 67 a can be larger than angle 67 c .
  • angle 67 c is approximately 170 degrees.
  • the sizes of leaflets 37 a - c and the angles 67 a - d can be modified in order to optimize the function of valve prosthesis 7 .
  • FIG. 7 shows an alternate valve prosthesis 101 having four leaflets 131 a - d and four commissure points 141 a - d .
  • Leaflets 131 a and 131 c are approximately the same size having approximately the same area. In an alternate aspect of the invention, leaflets 131 a and 131 c can be different sizes.
  • Leaflet 131 a is attached to leaflet 131 b at commissure point 141 a and to leaflet 131 d at commissure point 141 d .
  • Leaflet 131 c is attached to leaflet 131 b at commissure point 141 b and to leaflet 131 d at commissure point 141 c .
  • Free edges of leaflets 131 a and 131 b come together to form coaptation edge 151 a .
  • Free edges of leaflets 131 b and 131 c come together to form coaptation edge 151 b .
  • Free edges of leaflets 131 c and 131 d come together to form coaptation edge 151 c .
  • Free edges of leaflets 131 d and 131 a come together to form coaptation edge 151 d .
  • Free edges of leaflets 131 a and 131 c come together to form coaptation edge 151 e .
  • Coaptation edges 151 a - e thereby create a competent seal.
  • the length of coaptation edge 151 e is larger than the length of any of coaptation edges 151 a - d.
  • Leaflets 131 a - d are assembled to a skirt (not shown), similar to valve prosthesis 1 .
  • Commissure points 141 a - d are attached to frame 111 which is elliptical from a top view.
  • Commissure points 141 a - d are arranged to form angles 161 a - 161 d , where the center of frame 111 is the vertex of the angles.
  • Frame 111 can be any other shape known to a person of ordinary skill, including but not limited to circular, or D shaped from a top view, or tapered, conical, or cylindrical from a side view. In one aspect of the invention, angles 161 a and 161 c are larger than angles 161 b and 161 d .
  • angles 161 a and 161 c are approximately 170 degrees.
  • one or more of angles 161 a - d can be modified to optimize the function of valve prosthesis 101 by positioning one or more commissure points 141 a - d on an alternate portion of frame 111 or by modifying the shape or area of one or more of leaflets 131 a - d . Modifying one or more of angles 161 a - d can modify the length of coaptation edges 151 a - e.
  • frame 113 is D-Shaped.
  • leaflet 133 c has a larger area than leaflet 133 a and corresponding angle 163 c is greater than angle 163 a .
  • leaflet 133 a is larger than leaflets 133 b and 133 d and corresponding angle 163 a can be larger than angles 163 b and 163 d .
  • angle 163 c can be 170 degrees.
  • the sizes of leaflets 37 a - c and the angles 67 a - d can be modified to optimize the function of valve prosthesis 103 .
  • leaflets 133 a - d come together to form coaptation edges 153 a - e .
  • the length of coaptation edge 153 e is greater than the length of any of coaptation edges 153 a - d.
  • the valve prosthesis can replace the function of a tricuspid or bicuspid heart valve including the mitral valve, the aortic valve, the pulmonary valve, or the tricuspid valve.
  • the valve can be delivered, for example, transeptally, transapically, transradially, or transatrially.
  • the valve prosthesis preferably comprises a self-expanding frame that can be compressed to a contracted delivery configuration onto an inner member of a delivery catheter.
  • the valve prosthesis and inner member can then be loaded into a delivery sheath of conventional design, e.g., having a diameter of less than 20-24 French. Due in part to the fact that the commissure points are longitudinally offset from the coaptation edges of the leaflets, and due to the ability to maintain a lower commissure height, it is expected that the valve prosthesis can achieve a significantly smaller delivery profile than previously-known percutaneously-deliverable replacement valves.
  • the delivery catheter and valve prosthesis are then advanced in a retrograde manner through the femoral artery and into the patient's descending aorta.
  • the catheter then is advanced, under fluoroscopic guidance, over the aortic arch, through the ascending aorta and mid-way across the defective aortic valve. Once positioning of the catheter is confirmed, the sheath of the delivery catheter can be withdrawn proximally, thereby permitting the valve prosthesis to self-expand.
  • valve prosthesis As the valve prosthesis expands, it traps the leaflets of the patient's defective aortic valve against the valve annulus, retaining the native valve in a permanently open state.
  • the outflow section of the valve prosthesis expands against and aligns the prosthesis within the ascending aorta, while the inflow section becomes anchored in the aortic annulus of the left ventricle, so that the skirt reduces the risk of perivalvular leaks.
  • the valve prosthesis can be delivered through a transapical procedure.
  • a transapical procedure a trocar or overtube is inserted into the left ventricle through an incision created in the apex of a patient's heart.
  • a dilator is used to aid in the insertion of the trocar.
  • the native valve e.g. the mitral valve
  • the trocar is retracted sufficiently to release the self-expanding valve prosthesis.
  • the dilator is preferably presented between the valve leaflets.
  • the trocar can be rotated and adjusted as necessary to properly align the valve prosthesis.
  • the dilator is advanced into the left atrium to begin disengaging the proximal section of the valve prosthesis from the dilator.
  • the valve prosthesis can be delivered through a transatrial procedure.
  • the dilator and trocar are inserted through an incision made in the wall of the left atrium of the heart.
  • the dilator and trocar are advanced through the native valve and into the left ventricle of heart.
  • the dilator is then withdrawn from the trocar.
  • a guide wire is advanced through the trocar to the point where the valve prosthesis comes to the end of the trocar.
  • the valve prosthesis is advanced sufficiently to release the self-expanding frame from the trocar.
  • the trocar can be rotated and adjusted as necessary to properly align the valve prosthesis.
  • the trocar is completely withdrawn from the heart such that the valve prosthesis self-expands into position and assumes the function of the native valve.

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Transplantation (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Prostheses (AREA)

Abstract

Heart valve prostheses are provided having a self-expanding frame that supports a valve body comprising a skirt and a plurality of coapting leaflets. The leaflets are constructed with four commissure points to reduce the stress and strain applied to the commissure points and to efficiently distribute and transmit forces along the leaflets and to the frame.

Description

    BACKGROUND OF THE INVENTION Field of the Invention
  • The present invention is related to artificial heart valves. More specifically, the present invention is directed to an artificial valve prosthesis.
  • Background Art
  • Cardiac valves exhibit two types of pathologies: regurgitation and stenosis. Regurgitation is the more common of the two defects. Typically, either defect is treated by a surgical repair. Under certain conditions, however, the cardiac valve must be replaced. Standard approaches to valve replacement require cutting open the patient's chest and heart to access the native valve. Such procedures are traumatic to the patient, require a long recovery time, and can result in life threatening complications. Therefore, many patients requiring cardiac valve replacement are deemed to pose too high a risk for open heart surgery due to age, health, or a variety of other factors. These patient risks associated with heart valve replacement are lessened by the emerging techniques for minimally invasive valve repair, but still many of those techniques require arresting the heart and passing the blood through a heart-lung machine.
  • Efforts have been focused on percutaneous transluminal delivery of replacement cardiac valves to solve the problems presented by traditional open heart surgery and minimally-invasive surgical methods. In such methods, a valve prosthesis is compacted for delivery in a catheter and then advanced, for example, through an opening in the femoral artery and through the descending aorta to the heart, where the prosthesis is then deployed in the aortic valve annulus.
  • In view of the foregoing, it would be desirable to provide a valve prosthesis that is capable of conforming to a patient's anatomy while providing a uniform degree of rigidity and protection for critical valve components. Protection for critical valve components is essential to maintain reliability for the valve prosthesis.
  • BRIEF SUMMARY OF THE INVENTION
  • Provided herein are valve prostheses that generally include a self-expanding frame, where the valve prostheses are sutured to the self-expanding frame. Such configurations achieve numerous goals. For example, such configurations can: prevent the native leaflets from obstructing flow through the left ventricular outflow tract (LVOT); prevent the native leaflets from interacting with the prosthetic leaflets; recruit the native leaflets in minimizing perivalvular leaks; maintain proper alignment of the valve prosthesis; avoid systolic anterior mobility; and maintain valve stability by preventing migration of the valve into the atrium or ventricle. The design of the prosthesis also mimics the native valve and supports a non-round in vivo configuration, which better reproduces native valve function.
  • In view thereof, disclosed herein are aspects of a valve prosthesis which is generally designed to include a valve body and a self expanding frame. The valve body includes a first leaflet, a second leaflet, and a third leaflet. Adjoining leaflets are sewn together to form a first commissure point, a second commissure point, a third commissure point, and a fourth commissure point. The four commissure points are sewn to the frame.
  • In another exemplary embodiment, the valve prosthesis is designed to include a valve body including a first leaflet, a second leaflet, a third leaflet, and a fourth leaflet, and a self expanding frame. The first leaflet is attached to the second leaflet at a first point to form a first commissure point. The second leaflet is attached to the third leaflet at a second point to form a second commissure point. The third leaflet is attached to the fourth leaflet at a third point to form a third commissure point. The commissure points are sewn to the frame.
  • Disclosed herein are aspects of a method of treating a valve disorder in a patient's heart including loading a valve prosthesis onto a delivery system, advancing the delivery system and valve prosthesis through an incision into the patient's vasculature and into the patient's heart, releasing the valve prosthesis from the delivery system, and withdrawing the delivery system from the patient's heart. The valve prosthesis includes a valve body and a self-expanding frame. The valve body includes a first leaflet, a second leaflet, and a third leaflet. Adjoining leaflets are sewn together to form a first commissure point, a second commissure point, a third commissure point, and a fourth commissure point. The four commissure points are sewn to the frame.
  • BRIEF DESCRIPTION OF THE DRAWINGS/FIGURES
  • The accompanying figures, which are incorporated herein, form part of the specification and illustrate embodiments of a valve prosthesis. Together with the description, the figures further serve to explain the principles of and to enable a person skilled in the relevant art(s) to make, use, and implant the valve prosthesis described herein. In the drawings, like reference numbers indicate identical or functionally similar elements.
  • FIG. 1 is a perspective view of a valve prosthesis, in accordance with an aspect of the disclosure.
  • FIG. 2 is a side view of a valve prosthesis.
  • FIG. 3 is a top view of a valve prosthesis.
  • FIG. 4 is a top view of a valve prosthesis according to an alternate aspect of this disclosure.
  • FIG. 5 is a top view of a valve prosthesis according to an alternate aspect of this disclosure.
  • FIG. 6 is a top view of a valve prosthesis according to an alternate aspect of this disclosure.
  • FIG. 7 is a top view of a valve prosthesis according to an alternate aspect of this disclosure.
  • FIG. 8 is a top view of a valve prosthesis according to an alternate aspect of this disclosure.
  • DETAILED DESCRIPTION OF THE INVENTION
  • The following detailed description of a valve prosthesis refers to the accompanying figures that illustrate exemplary embodiments. Other embodiments are possible. Modifications can be made to the embodiments described herein without departing from the spirit and scope of the present invention. Therefore, the following detailed description is not meant to be limiting.
  • The present invention is directed to a heart valve prosthesis having a self-expanding frame that supports a valve body. The valve prosthesis can be delivered percutaneously to the heart to replace the function of a native valve. For example, the valve prosthesis can replace a bicuspid or a tricuspid valve such as the aortic, mitral, pulmonary, or tricuspid heart valve.
  • In one aspect of the invention, the valve body comprises three leaflets that are fastened together at enlarged lateral end regions to form commissural joints, with the unattached edges forming the coaptation edges of the valve. The leaflets can be fastened to a skirt, which in turn can be attached to the frame. The upper ends of the commissure points define an outflow or proximal portion of the valve prosthesis. The opposite end of the valve at the skirt defines an inflow or distal portion of the valve prosthesis. The enlarged lateral end regions of the leaflets permit the material to be folded over to enhance durability of the valve and reduce stress concentration points that could lead to fatigue or tearing of the leaflets. The commissural joints are attached above the plane of the coaptation edges of the valve body to minimize the contacted delivery profile of the valve prosthesis.
  • Referring to FIGS. 1 and 2, from a top view, valve prosthesis 1 includes a circular frame 11. Frame 11 can be any non-biological structure including wireforms, stents, and the like. In alternate aspects of the invention, frame 11 can be elliptical, D-shaped, or any other shape known to a person of ordinary skill in the art. From a side view, frame 11 can be tapered, cylindrical, conical, or any other shape known to a person of ordinary skill. Frame 11 can be a self-expanding structure formed by laser cutting or etching a metal alloy tube comprising, for example a shape memory material such as nickel titanium (nitinol). Alternatively, frame 11 can be a balloon expanding structure. Frame 11 can include a pattern of radial cells that make up the structure of frame 11. The cell sizes can be modified during the formation of frame 11, for example through an expansion step. In addition, the number of cells in a radial or axial direction can be modified to allow for a larger or fewer number of cells. Frame 11 can also include a cusp 91. Cusp 91 can be a radiopaque imaging reference to assist in positioning the valve prosthesis 1 in a native valve annulus. Cusp 91 can also assist in anchoring frame 11 in the native valve annulus.
  • Valve prosthesis 1 also includes a valve 21 that includes individual leaflets that are assembled to the skirt. The leaflets and skirt are formed from a natural or man-made material. Preferred materials for valve 21 include mammalian tissue, such as porcine, equine, or bovine pericardium, or a synthetic or polymeric material. In one aspect of the invention, valve 21 includes three leaflets 31 a-c. Adjoining pairs of leaflets are attached to one another to form commissure points 41 a-d. Leaflet 31 b is attached to leaflet 31 a by commissure points 41 a and 41 d. Leaflet 31 b is attached to leaflet 31 c by commissure points 41 b and 41 c. In a preferred embodiment, valve prosthesis 1 is biased to a closed position. Alternatively, valve prosthesis 1 can be biased to an open position. Free edges of leaflets 31 b and 31 a come together to form coaptation edge 51 a, thereby creating a competent seal. Free edges of leaflets 31 b and 31 c come together to form coaptation edge 51 b, thereby creating a competent seal. The length of coaptation edges 51 a and 51 b can be from approximately 24 mm to approximately 48 mm. In a preferred embodiment, the length of coaptation edges 51 a and 51 b is approximately 25 mm.
  • In one aspect of the invention, the contact area between the leaflets at coaptation edges 51 a and 51 b is minimized to allow for quicker opening and closing of valve leaflets 31 a-c. For example, at coaptation edge 51 a, approximately 0.5 mm to approximately 6 mm of valve leaflets 31 a and 31 b touch along the length of coaptation edge 51 a. However, the contact area of the leaflets at coaptation edges 51 a and 51 b is affected by the positioning of valve prosthesis 1 in the native anatomy. In one aspect of the invention, after implantation, valve prosthesis 1 takes approximately 0.06 seconds to open from a closed configuration. Valve prosthesis 1 takes approximately 0.04 seconds to close from an open configuration. Valve prosthesis 1 is also able to operate at approximately 167 ml/second of fluid.
  • The bases of leaflets 31 a-c are assembled to a skirt 71 and attached to frame 11. Commissure points 41 a-d are positioned on frame 11 such that leaflet 31 b extends across the center of frame 11, as shown in FIG. 3. Valve prosthesis 1 can include center member 81. In one aspect of the invention, center member 81 attaches to frame 11 between commissure points 41 a and 41 b and between commissure points 41 c and 41 d. Center member 81 can be semi-rigid or rigid and can be a suture, nitinol wire, or a synthetic or polymeric material that will not generate a thrombotic response in a patient, or any other material known to a person of ordinary skill in the art. In one aspect of the invention, center member 81 is attached to frame 11 on the outflow side of leaflet 31 b. Alternatively, center member 81 can be attached to frame 11 on the inflow side of leaflet 31 b. Center member 81 restricts the movement of leaflet 31 b and prevents leaflet 31 b from collecting blood and parachuting in the outflow direction in the presence of blood flow. As a result, during blood flow, the free edges of leaflet 31 b fold along center member 81 and minimize the area of leaflet 31 b extending across the orifice area of valve prosthesis 1.
  • In another aspect of the invention, each commissure point is attached to frame 11 by sewing the commissure point to a cell of frame 11 such that each commissure point occupies an entire cell of frame 11. Alternatively, each commissure point can be attached to frame 11 by sewing the commissure point to a portion of a cell of frame 11. In a preferred embodiment, at least one cell of frame 11 is positioned between commissure points 41 a and 41 b and commissure points 41 c and 41 d. Further, at least two cells can be positioned between commissure points 41 b and 41 c and commissure points 41 a and 41 d. In one aspect of the invention, commissure points 41 a-d are disposed longitudinally offset from coaptation edges 51 a-b of the valve body, thereby permitting a smaller delivery profile. Due to the presence of leaflet 31 b across the center of frame 11, valve prosthesis 1 may require a delivery system that features an asymmetric member so that the delivery system doesn't interfere with leaflet 31 b. Alternatively, a delivery system for valve prosthesis 1 can grasp the outer edge of frame 11 to deliver valve prosthesis 1 into a native valve annulus.
  • The axial distance from the distal most portion of the base of the valve leaflets to the proximal most portion of the valve leaflets is the leaflet height, h2. The base of the valve leaflets is where the leaflet edges attach to the skirt and the valve frame. In a preferred embodiment, h2 is from approximately 8 mm to approximately 15 mm. The axial distance between the distal and proximal portions of the commissure points is the commissure height, h1. In a preferred embodiment, h1 is approximately 9 mm.
  • FIG. 3 shows valve 21 in the closed state. Commissure points 41 a-d attach to frame 11 and are positioned to form angles 61 a-d between the respective commissure points with the center of frame 11 as the vertex of the angles. Angles 61 a and 61 c can be larger than angles 61 b and 61 d. In one aspect of the invention, angles 61 a and 61 c are approximately 170 degrees. In an alternate embodiment, one or more of angles 61 a-d can be modified to optimize the function of valve prosthesis 1 by positioning one or more commissure points 41 a-d at an alternate portion or cell of frame 11 or by modifying the shape of one or more of leaflets 31 a-c. For example, angles 61 a and 61 c can be between approximately 160 degrees and 180 degrees. Angles 61 a and 61 c can also be between 90 degrees and 180 degrees. Modifying one or more of angles 61 a-d can modify the length of coaptation edges 51 a and/or 51 b. A longer coaptation edge length correlates to less stress on commissure points 41 a-d.
  • In a further aspect of the invention, leaflets 31 a and 31 c are approximately the same size. Alternatively, leaflets 31 a and 31 c can be different sizes. Modifying the sizes of leaflets 31 a and 31 c can also affect angles 61 a-d. For example, if leaflets 31 a and 31 c are different sizes, angle 61 c can be larger than angle 61 a, or vice versa.
  • The configuration involving four commissure points can increase the coaptation length of the valve leaflets. As a result, the four commissure points experience less deflection than a valve having three commissure points. This allows the leaflets to maintain a rapid opening and closing time. The four commissure design also enables the valve prosthesis to maintain reliability with a low commissure height. The low commissure height allows valve prosthesis 1 to replace the native mitral valve. Furthermore, a low commissure height correlates to a valve prosthesis that is shorter in the axial direction that is easier to position and align in a native valve annulus. The four commissure points also enable the valve to maintain hemodynamic performance in a severely elliptical configuration by mitigating impact in the coaptive region. This configuration also provides a more uniform distribution of stresses along coaptation edges 51 a-b of leaflets 31 a-c allowing valve prosthesis 1 to exhibit greater reliability and a longer operating life than current catheter delivered valve prostheses.
  • In an alternate aspect of the invention shown in FIG. 4, from a side view, frame 13 is an hourglass shape where the outflow portion flares out such that the diameter of the outflow portion of the frame is larger than the diameter of the inflow portion of the frame. In one aspect of the invention, commissure points 43 a-d are angled outward from the center of frame 13. In this configuration, the most proximal portions of commissure points 43 a-d are further from the center of frame 13 than the distal portions of commissure points 43 a-d. In an alternate embodiment, the commissure points can be angled inward towards the center of the frame. The commissure points can also be oriented vertically on the frame, as shown in FIG. 3.
  • FIGS. 5-6 are top views of alternative aspects of the invention showing alternate frame shapes. In FIG. 5, from a top view, the frame is an elliptical shape. In this embodiment, leaflets 35 a and 35 c have approximately the same size and area and angles 65 a and 65 c are approximately equal. In a preferred embodiment, angles 65 a and 65 c are approximately 170 degrees. Furthermore, coaptation edges 55 a and 55 b are approximately equal in length. Similar to valve prosthesis 1 discussed in FIGS. 1-3, the size and area of leaflets 35 a-c can be modified so that leaflets 35 a and 35 c do not have approximately the same size. The placement of commissure points 45 a-d on frame 15 can also be modified to alter angles 65 a-d in order to optimize the function of valve prosthesis 5.
  • In FIG. 6, from a top view, frame 17 is D-Shaped. In this aspect of the invention, leaflet 37 c can have a larger area than leaflet 37 a and corresponding angle 67 c can be greater than angle 67 a. As a result, coaptation edge 57 b can have a greater length than coaptation edge 57 a. Alternatively, leaflet 37 a can be larger than leaflets 37 c and corresponding angle 67 a can be larger than angle 67 c. In a preferred embodiment, angle 67 c is approximately 170 degrees. In alternate aspects of the invention, the sizes of leaflets 37 a-c and the angles 67 a-d can be modified in order to optimize the function of valve prosthesis 7.
  • FIG. 7 shows an alternate valve prosthesis 101 having four leaflets 131 a-d and four commissure points 141 a-d. Leaflets 131 a and 131 c are approximately the same size having approximately the same area. In an alternate aspect of the invention, leaflets 131 a and 131 c can be different sizes. Leaflet 131 a is attached to leaflet 131 b at commissure point 141 a and to leaflet 131 d at commissure point 141 d. Leaflet 131 c is attached to leaflet 131 b at commissure point 141 b and to leaflet 131 d at commissure point 141 c. Free edges of leaflets 131 a and 131 b come together to form coaptation edge 151 a. Free edges of leaflets 131 b and 131 c come together to form coaptation edge 151 b. Free edges of leaflets 131 c and 131 d come together to form coaptation edge 151 c. Free edges of leaflets 131 d and 131 a come together to form coaptation edge 151 d. Free edges of leaflets 131 a and 131 c come together to form coaptation edge 151 e. Coaptation edges 151 a-e thereby create a competent seal. In a preferred embodiment, the length of coaptation edge 151 e is larger than the length of any of coaptation edges 151 a-d.
  • Leaflets 131 a-d are assembled to a skirt (not shown), similar to valve prosthesis 1. Commissure points 141 a-d are attached to frame 111 which is elliptical from a top view. Commissure points 141 a-d are arranged to form angles 161 a-161 d, where the center of frame 111 is the vertex of the angles. Frame 111 can be any other shape known to a person of ordinary skill, including but not limited to circular, or D shaped from a top view, or tapered, conical, or cylindrical from a side view. In one aspect of the invention, angles 161 a and 161 c are larger than angles 161 b and 161 d. In a preferred embodiment, angles 161 a and 161 c are approximately 170 degrees. In an alternate embodiment, one or more of angles 161 a-d can be modified to optimize the function of valve prosthesis 101 by positioning one or more commissure points 141 a-d on an alternate portion of frame 111 or by modifying the shape or area of one or more of leaflets 131 a-d. Modifying one or more of angles 161 a-d can modify the length of coaptation edges 151 a-e.
  • In an alternate aspect of the invention shown in FIG. 8, from a top view, frame 113 is D-Shaped. In this aspect of the invention, leaflet 133 c has a larger area than leaflet 133 a and corresponding angle 163 c is greater than angle 163 a. Furthermore, leaflet 133 a is larger than leaflets 133 b and 133 d and corresponding angle 163 a can be larger than angles 163 b and 163 d. In a preferred embodiment, angle 163 c can be 170 degrees. In alternate aspects of the invention, the sizes of leaflets 37 a-c and the angles 67 a-d can be modified to optimize the function of valve prosthesis 103. Similar to valve prosthesis 101 discussed above with respect to FIG. 7, leaflets 133 a-d come together to form coaptation edges 153 a-e. In a preferred embodiment, the length of coaptation edge 153 e is greater than the length of any of coaptation edges 153 a-d.
  • The valve prosthesis can replace the function of a tricuspid or bicuspid heart valve including the mitral valve, the aortic valve, the pulmonary valve, or the tricuspid valve. The valve can be delivered, for example, transeptally, transapically, transradially, or transatrially.
  • Implantation of the valve prosthesis will now be described. As discussed above, the valve prosthesis preferably comprises a self-expanding frame that can be compressed to a contracted delivery configuration onto an inner member of a delivery catheter. The valve prosthesis and inner member can then be loaded into a delivery sheath of conventional design, e.g., having a diameter of less than 20-24 French. Due in part to the fact that the commissure points are longitudinally offset from the coaptation edges of the leaflets, and due to the ability to maintain a lower commissure height, it is expected that the valve prosthesis can achieve a significantly smaller delivery profile than previously-known percutaneously-deliverable replacement valves.
  • The delivery catheter and valve prosthesis are then advanced in a retrograde manner through the femoral artery and into the patient's descending aorta. The catheter then is advanced, under fluoroscopic guidance, over the aortic arch, through the ascending aorta and mid-way across the defective aortic valve. Once positioning of the catheter is confirmed, the sheath of the delivery catheter can be withdrawn proximally, thereby permitting the valve prosthesis to self-expand.
  • As the valve prosthesis expands, it traps the leaflets of the patient's defective aortic valve against the valve annulus, retaining the native valve in a permanently open state. The outflow section of the valve prosthesis expands against and aligns the prosthesis within the ascending aorta, while the inflow section becomes anchored in the aortic annulus of the left ventricle, so that the skirt reduces the risk of perivalvular leaks.
  • Alternatively, the valve prosthesis can be delivered through a transapical procedure. In a transapical procedure, a trocar or overtube is inserted into the left ventricle through an incision created in the apex of a patient's heart. A dilator is used to aid in the insertion of the trocar. In this approach, the native valve (e.g. the mitral valve) is approached from the downstream relative to the blood flow. The trocar is retracted sufficiently to release the self-expanding valve prosthesis. The dilator is preferably presented between the valve leaflets. The trocar can be rotated and adjusted as necessary to properly align the valve prosthesis. The dilator is advanced into the left atrium to begin disengaging the proximal section of the valve prosthesis from the dilator.
  • In an alternate aspect of the invention, the valve prosthesis can be delivered through a transatrial procedure. In this procedure, the dilator and trocar are inserted through an incision made in the wall of the left atrium of the heart. The dilator and trocar are advanced through the native valve and into the left ventricle of heart. The dilator is then withdrawn from the trocar. A guide wire is advanced through the trocar to the point where the valve prosthesis comes to the end of the trocar. The valve prosthesis is advanced sufficiently to release the self-expanding frame from the trocar. The trocar can be rotated and adjusted as necessary to properly align the valve prosthesis. The trocar is completely withdrawn from the heart such that the valve prosthesis self-expands into position and assumes the function of the native valve.
  • The foregoing description has been presented for purposes of illustration and enablement, and is not intended to be exhaustive or to limit the invention to the precise form disclosed. Other modifications and variations are possible in light of the above teachings. The embodiments and examples were chosen and described in order to best explain the principles of the invention and its practical application and to thereby enable others skilled in the art to best utilize the invention in various embodiments and various modifications as are suited to the particular use contemplated. It is intended that the appended claims be construed to include other alternative embodiments of the invention.

Claims (8)

1-10. (canceled)
11: A valve prosthesis comprising:
a valve body including a first leaflet, a second leaflet, a third leaflet, and a fourth leaflet; and
a self-expanding frame,
wherein the first leaflet is attached to the second leaflet at a first commissure point, the second leaflet is attached to the third leaflet at a second commissure point, the third leaflet is attached to the fourth leaflet at a third commissure point, the fourth leaflet is attached to the first leaflet at a fourth commissure point,
wherein the first, second, third and fourth commissure points are sewn to the frame,
wherein a first free portion of the first leaflet and a first free portion of the second leaflet form a first coaptive edge, a second free portion of the second leaflet and a first free portion of the third leaflet form a second coaptive edge, a second free portion of the third leaflet and a first free portion of the fourth leaflet form a third coaptive edge, a second free portion of the fourth leaflet and a second free portion of the first leaflet form a fourth coaptive edge, and a third free portion of the first leaflet and a third free portion of the third leaflet form a fifth coaptive edge,
wherein the fifth coaptive edge is greater in length than each of the first, second, third, and fourth coaptive edges; and
wherein the second coaptive edge and the third coaptive edge are approximately equal in length, and wherein the second coaptive edge and the third coaptive edge are greater in length than the first coaptive edge and the fourth coaptive edge.
12: The valve prosthesis according to claim 11, wherein the first commissure point and the second commissure point form a first angle with a vertex of the first angle being a center of the frame, the second commissure point and the third commissure point form a second angle with a vertex of the second angle being the center of the frame, the third commissure point and the fourth commissure point form a third angle with a vertex of the third angle being the center of the frame, and the fourth commissure point and the first commissure point form a fourth angle with a vertex of the fourth angle being the center of the frame, such that the vertex of each of the first, second, third and fourth angles are at the center of the frame,
wherein each of the second angle and the fourth angle are greater than each of the first angle and the third angle, and
wherein the second angle is greater than the fourth angle.
13-21. (canceled)
22: A valve prosthesis comprising:
a valve body including a first leaflet, a second leaflet, a third leaflet, and a fourth leaflet; and
a self-expanding frame,
wherein the first leaflet is attached to the second leaflet at a first commissure point, the second leaflet is attached to the third leaflet at a second commissure point, the third leaflet is attached to the fourth leaflet at a third commissure point, the fourth leaflet is attached to the first leaflet at a fourth commissure point,
wherein the first, second, third and fourth commissure points are sewn to the frame,
wherein a first angle is formed between the first commissure point and the second commissure point with a vertex of the first angle being a center of the frame, a second angle is formed between the second commissure point and the third commissure point with a vertex of the second angle being the center of the frame, a third angle is formed between the third commissure point and the fourth commissure point with a vertex of the third angle being the center of the frame, and a fourth angle is formed between the fourth commissure point and the first commissure point with a vertex of the fourth angle being the center of the frame, such that the vertex of each of the first, second, third and fourth angles are at the center of the frame, and
wherein the second angle and the fourth angle are greater than the first angle and the third angle, and
wherein the second angle is greater than the fourth angle.
23: The valve prosthesis according to claim 22, wherein a first free portion of the first leaflet and a first free portion of the second leaflet form a first coaptive edge, a second free portion of the second leaflet and a first free portion of the third leaflet form a second coaptive edge, a second free portion of the third leaflet and a first free portion of the fourth leaflet form a third coaptive edge, a second free portion of the fourth leaflet and a second free portion of the first leaflet form a fourth coaptive edge, and a third free portion of the first leaflet and a third free portion of the third leaflet form a fifth coaptive edge,
wherein the fifth coaptive edge is greater in length than each of the first, second, third, and fourth coaptive edges, and
wherein the second coaptive edge and the third coaptive edge are approximately equal in length, and wherein the second coaptive edge and the third coaptive edge are greater in length than the first coaptive edge and the fourth coaptive edge.
24: A valve prosthesis comprising:
a valve body including a first leaflet, a second leaflet, a third leaflet, and a fourth leaflet, wherein the third leaflet has a larger area than the first leaflet, and the first leaflet has a larger area than each of the second and third leaflets; and
a self-expanding frame, wherein the first, second, third and fourth leaflets are attached to the frame, and
wherein a first free portion of the first leaflet and a first free portion of the second leaflet form a first coaptive edge, a second free portion of the second leaflet and a first free portion of the third leaflet form a second coaptive edge, a second free portion of the third leaflet and a first free portion of the fourth leaflet form a third coaptive edge, a second free portion of the fourth leaflet and a second free portion of the first leaflet form a fourth coaptive edge, and a third free portion of the first leaflet and a third free portion of the third leaflet form a fifth coaptive edge,
wherein the fifth coaptive edge is greater in length than each of the first, second, third, and fourth coaptive edges, and.
wherein the second coaptive edge and the third coaptive edge are approximately equal in length, and wherein the second coaptive edge and the third coaptive edge are greater in length than the first coaptive edge and the fourth coaptive edge.
25: The valve prosthesis according to claim 24, wherein the frame is D-shaped.
US15/945,514 2012-03-30 2018-04-04 Valve prosthesis Abandoned US20180221145A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US15/945,514 US20180221145A1 (en) 2012-03-30 2018-04-04 Valve prosthesis

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13/435,802 US9101467B2 (en) 2012-03-30 2012-03-30 Valve prosthesis
US14/799,410 US9937035B2 (en) 2012-03-30 2015-07-14 Valve prosthesis
US15/945,514 US20180221145A1 (en) 2012-03-30 2018-04-04 Valve prosthesis

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US14/799,410 Division US9937035B2 (en) 2012-03-30 2015-07-14 Valve prosthesis

Publications (1)

Publication Number Publication Date
US20180221145A1 true US20180221145A1 (en) 2018-08-09

Family

ID=47827463

Family Applications (3)

Application Number Title Priority Date Filing Date
US13/435,802 Active 2033-07-15 US9101467B2 (en) 2012-03-30 2012-03-30 Valve prosthesis
US14/799,410 Active 2032-09-23 US9937035B2 (en) 2012-03-30 2015-07-14 Valve prosthesis
US15/945,514 Abandoned US20180221145A1 (en) 2012-03-30 2018-04-04 Valve prosthesis

Family Applications Before (2)

Application Number Title Priority Date Filing Date
US13/435,802 Active 2033-07-15 US9101467B2 (en) 2012-03-30 2012-03-30 Valve prosthesis
US14/799,410 Active 2032-09-23 US9937035B2 (en) 2012-03-30 2015-07-14 Valve prosthesis

Country Status (3)

Country Link
US (3) US9101467B2 (en)
EP (2) EP3326584B1 (en)
WO (1) WO2013148020A1 (en)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9730790B2 (en) 2009-09-29 2017-08-15 Edwards Lifesciences Cardiaq Llc Replacement valve and method
US8579964B2 (en) 2010-05-05 2013-11-12 Neovasc Inc. Transcatheter mitral valve prosthesis
US9308087B2 (en) 2011-04-28 2016-04-12 Neovasc Tiara Inc. Sequentially deployed transcatheter mitral valve prosthesis
US9554897B2 (en) 2011-04-28 2017-01-31 Neovasc Tiara Inc. Methods and apparatus for engaging a valve prosthesis with tissue
US9345573B2 (en) 2012-05-30 2016-05-24 Neovasc Tiara Inc. Methods and apparatus for loading a prosthesis onto a delivery system
AU2013224679A1 (en) * 2012-09-04 2014-03-20 Negri, Justin MR "Prosthetic heart valve"
US9681951B2 (en) 2013-03-14 2017-06-20 Edwards Lifesciences Cardiaq Llc Prosthesis with outer skirt and anchors
US9572665B2 (en) 2013-04-04 2017-02-21 Neovasc Tiara Inc. Methods and apparatus for delivering a prosthetic valve to a beating heart
US8870948B1 (en) 2013-07-17 2014-10-28 Cephea Valve Technologies, Inc. System and method for cardiac valve repair and replacement
EP4176844A1 (en) * 2013-11-06 2023-05-10 St. Jude Medical, Cardiology Division, Inc. Reduced profile prosthetic heart valve
WO2016007652A1 (en) 2014-07-08 2016-01-14 Avinger, Inc. High speed chronic total occlusion crossing devices
WO2016093877A1 (en) 2014-12-09 2016-06-16 Cephea Valve Technologies, Inc. Replacement cardiac valves and methods of use and manufacture
EP3294220B1 (en) 2015-05-14 2023-12-06 Cephea Valve Technologies, Inc. Cardiac valve delivery devices and systems
EP3294221B1 (en) 2015-05-14 2024-03-06 Cephea Valve Technologies, Inc. Replacement mitral valves
US20160346081A1 (en) * 2015-05-25 2016-12-01 Horizon Scientific Corp. Transcatheter Pulmonary Ball Valve Assembly
US10052202B2 (en) 2015-05-25 2018-08-21 Venus Medtech (Hangzhou) Inc Transcatheter pulmonary ball valve assembly
CN108601645B (en) 2015-12-15 2021-02-26 内奥瓦斯克迪亚拉公司 Transseptal delivery system
EP4183372A1 (en) 2016-01-29 2023-05-24 Neovasc Tiara Inc. Prosthetic valve for avoiding obstruction of outflow
EP3471665B1 (en) 2016-06-17 2023-10-11 Cephea Valve Technologies, Inc. Cardiac valve delivery devices
EP3541462A4 (en) 2016-11-21 2020-06-17 Neovasc Tiara Inc. Methods and systems for rapid retraction of a transcatheter heart valve delivery system
US10653523B2 (en) 2017-01-19 2020-05-19 4C Medical Technologies, Inc. Systems, methods and devices for delivery systems, methods and devices for implanting prosthetic heart valves
CA3051272C (en) 2017-01-23 2023-08-22 Cephea Valve Technologies, Inc. Replacement mitral valves
EP4209196A1 (en) 2017-01-23 2023-07-12 Cephea Valve Technologies, Inc. Replacement mitral valves
US10561495B2 (en) 2017-01-24 2020-02-18 4C Medical Technologies, Inc. Systems, methods and devices for two-step delivery and implantation of prosthetic heart valve
US12029647B2 (en) 2017-03-07 2024-07-09 4C Medical Technologies, Inc. Systems, methods and devices for prosthetic heart valve with single valve leaflet
US12036113B2 (en) 2017-06-14 2024-07-16 4C Medical Technologies, Inc. Delivery of heart chamber prosthetic valve implant
US10856984B2 (en) 2017-08-25 2020-12-08 Neovasc Tiara Inc. Sequentially deployed transcatheter mitral valve prosthesis
US11857441B2 (en) 2018-09-04 2024-01-02 4C Medical Technologies, Inc. Stent loading device
WO2020060828A1 (en) * 2018-09-20 2020-03-26 St. Jude Medical, Cardiology Division, Inc. Attachment of leaflets to prosthetic heart valve
AU2019374743B2 (en) 2018-11-08 2022-03-03 Neovasc Tiara Inc. Ventricular deployment of a transcatheter mitral valve prosthesis
CA3132873A1 (en) 2019-03-08 2020-09-17 Neovasc Tiara Inc. Retrievable prosthesis delivery system
CN113811265A (en) 2019-04-01 2021-12-17 内奥瓦斯克迪亚拉公司 Prosthetic valve deployable in a controlled manner
AU2020271896B2 (en) 2019-04-10 2022-10-13 Neovasc Tiara Inc. Prosthetic valve with natural blood flow
WO2020236931A1 (en) 2019-05-20 2020-11-26 Neovasc Tiara Inc. Introducer with hemostasis mechanism
WO2020257643A1 (en) 2019-06-20 2020-12-24 Neovasc Tiara Inc. Low profile prosthetic mitral valve
US11931253B2 (en) 2020-01-31 2024-03-19 4C Medical Technologies, Inc. Prosthetic heart valve delivery system: ball-slide attachment
EP4114308A1 (en) * 2020-03-02 2023-01-11 Biotronik AG Heart valve prosthesis
US12053375B2 (en) 2020-03-05 2024-08-06 4C Medical Technologies, Inc. Prosthetic mitral valve with improved atrial and/or annular apposition and paravalvular leakage mitigation
US11992403B2 (en) 2020-03-06 2024-05-28 4C Medical Technologies, Inc. Devices, systems and methods for improving recapture of prosthetic heart valve device with stent frame having valve support with inwardly stent cells
CN111407466A (en) * 2020-03-27 2020-07-14 山东大学齐鲁医院 Implantable biological valve
CN111904661B (en) * 2020-06-04 2022-12-02 金仕生物科技(常熟)有限公司 Bileaflet valve prosthesis
CN111991119B (en) * 2020-09-14 2022-10-21 金仕生物科技(常熟)有限公司 Bileaflet valve prosthesis with valve ears

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050192665A1 (en) * 2001-10-11 2005-09-01 Benjamin Spenser Implantable prosthetic valve
US20070050021A1 (en) * 2005-08-25 2007-03-01 Derrick Johnson Four-leaflet stented mitral heart valve
US20140155995A1 (en) * 2011-02-25 2014-06-05 University Of Connecticut Prosthetic heart valve

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7404824B1 (en) 2002-11-15 2008-07-29 Advanced Cardiovascular Systems, Inc. Valve aptation assist device
CA2580053C (en) 2004-09-14 2014-07-08 Edwards Lifesciences Ag. Device and method for treatment of heart valve regurgitation
US8092525B2 (en) 2005-10-26 2012-01-10 Cardiosolutions, Inc. Heart valve implant

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050192665A1 (en) * 2001-10-11 2005-09-01 Benjamin Spenser Implantable prosthetic valve
US20070050021A1 (en) * 2005-08-25 2007-03-01 Derrick Johnson Four-leaflet stented mitral heart valve
US20140155995A1 (en) * 2011-02-25 2014-06-05 University Of Connecticut Prosthetic heart valve

Also Published As

Publication number Publication date
EP3326584B1 (en) 2020-09-30
EP2830534A1 (en) 2015-02-04
US9937035B2 (en) 2018-04-10
EP3326584A1 (en) 2018-05-30
US20130261740A1 (en) 2013-10-03
US9101467B2 (en) 2015-08-11
EP2830534B1 (en) 2017-12-20
WO2013148020A1 (en) 2013-10-03
US20150313710A1 (en) 2015-11-05

Similar Documents

Publication Publication Date Title
US9937035B2 (en) Valve prosthesis
US11833038B2 (en) Valve prosthesis and method for delivery
US10945841B2 (en) Valve prosthesis and method for delivery
US11717401B2 (en) Prosthetic heart valve assembly
US10398546B2 (en) Mitral prosthesis and methods for implantation
US9999501B2 (en) Valve prosthesis
US20140114408A1 (en) Valve Prosthesis
US20230149162A1 (en) Prosthetic heart valve

Legal Events

Date Code Title Description
AS Assignment

Owner name: MEDTRONIC CV LUXEMBOURG S.A.R.L., LUXEMBOURG

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:EBERHARDT, CAROL;LO, PHAM;MCNATT, TOMAS;SIGNING DATES FROM 20120316 TO 20120319;REEL/FRAME:045438/0915

STPP Information on status: patent application and granting procedure in general

Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: FINAL REJECTION MAILED

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION